Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Clin Pharmacol Ther. 2020 Feb 13;108(1):116–125. doi: 10.1002/cpt.1768

Table 5:

Recommendations for FDA Table of Inhibitors

Moderate Inhibitor Weak Inhibitor Removal from table
cimetidine, cinacalcet, duloxetine, fluvoxamine, mirabegrona abiraterone, amiodarone, celecoxibb, cimetidine, clobazam, cobicistat, desvenlafaxine, escitalopram, fluvoxamine, labetalol, lorcaserin, ritonavir, sertraline, vemurafenib Desvenlafaxine
a,

Genotype should be considered, appears to moderately inhibit only when individuals are NMs

b,

Only at doses > 200 mg total daily dose